Tetraphase Pharmaceuticals, Inc.
TTPH
TTPH was delisted on the 28th of July, 2020.
94 hedge funds and large institutions have $204M invested in Tetraphase Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 17 reducing their positions, and 13 closing their positions.
124% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 17
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
34% more capital invested
Capital invested by funds: $152M → $204M (+$52.3M)
4% more funds holding
Funds holding: 90 → 94 (+4)
67% less call options, than puts
Call options by funds: $1.16M | Put options by funds: $3.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$9.93M |
| 2 |
JP Morgan Chase
New York
|
+$8.02M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$7.98M |
| 4 |
BlackRock
New York
|
+$6.48M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$6.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.52M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.35M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$2.14M |
| 4 |
DAM
DLD Asset Management
New York
|
-$1.64M |
| 5 |
Morgan Stanley
New York
|
-$1.62M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
101
Boothbay Fund Management
New York
| – | -$453K | -3,180 | Closed |
|
|
QIM
102
Quantitative Investment Management
Charlottesville,
Virginia
| – | -$271K | -1,905 | Closed |
|
|
WVP
103
Worth Venture Partners
Fort Lee,
New Jersey
| – | -$209K | -1,466 | Closed |
|
|
GCP
104
GSA Capital Partners
London,
United Kingdom
| – | -$205K | -1,440 | Closed |
|
|
TI
105
Trexquant Investment
Stamford,
Connecticut
| – | -$156K | -1,095 | Closed |
|
106
UBS Group
Zurich,
Switzerland
| – | -$5K | -33 | Closed |
|
|
SPIA
107
Steward Partners Investment Advisory
New York
| – | +$669 | +5 | New |
|
TTPH Hedge Fund Activity: Q3 2017 in Review
94 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q3 2017, worth a combined $204M — up 34% from $152M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TTPH positions and 13 closed out — a net gain of 5 holders — while 38 added to existing stakes and 17 trimmed.
The largest buyer was Millennium Management, adding an estimated $9.93M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $4.52M sold.
- 94 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q3 2017, up from 90 in Q2 2017.
- Funds reported $204M of Tetraphase Pharmaceuticals, Inc. stock for Q3 2017, up 34% quarter-over-quarter.
- 18 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q3 2017 and 13 closed out, a net change of +5 holders.
- The largest Tetraphase Pharmaceuticals, Inc. buyer in Q3 2017 was Millennium Management, an estimated $9.93M added.
- The largest Tetraphase Pharmaceuticals, Inc. seller in Q3 2017 was EcoR1 Capital, an estimated $4.52M sold.
Based on aggregated 13F filings for Q3 2017.